<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897011</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-IMJ-003</org_study_id>
    <nct_id>NCT02897011</nct_id>
  </id_info>
  <brief_title>2-week dc of MTX and Influenza Vaccination in RA</brief_title>
  <acronym>2 wk MTX</acronym>
  <official_title>Effect of Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether a transient discontinuation of methotrexate MTX for 2 weeks improves&#xD;
      the vaccination response to a seasonal influenza.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects the joints&#xD;
      as the main target of the inflammation. Patients with RA require chronic treatment with&#xD;
      disease modifying antirheumatic drugs (DMARDs) including methotrexate (MTX), which&#xD;
      constitutes the mainstay of treatment. Underlying immune dysfunction and the additional&#xD;
      immune suppression associated with treatment render patients with RA more susceptible to&#xD;
      infection. Thus, vaccination of the preventive diseases is crucial and recommended in all&#xD;
      patients unless contraindicated.&#xD;
&#xD;
      However, low dose of glucocorticoids, conventional DMARDs and biological DMARDs including&#xD;
      tumor necrosis factor inhibitors have been reported to substantially decrease vaccine&#xD;
      response (4); MTX has been reported to be associated with a decreased response to seasonal&#xD;
      influenza vaccination by up to 15%.&#xD;
&#xD;
      To optimize a vaccine response, vaccination should be administrated before the treatment with&#xD;
      immunesuppressive medications is initiated. However, most patients with RA are already on&#xD;
      stable dose of MTX at the time of when vaccinations. To improve the vaccine response, a short&#xD;
      term discontinuation of MTX could be considered. In a prior study, we discovered that a&#xD;
      temporary discontinuation of MTX for 4 weeks during peri-vaccination period tended to be&#xD;
      associated with an improved response to vaccination with trivalent influenza vaccination&#xD;
      (Figure 1). It remains to be defined whether MTX discontinuation for shorter period increases&#xD;
      the vaccination efficacy while minimizing the RA flare rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of satisfactory vaccine response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of satisfactory vaccine response that is defined as ≥ 4-fold increase in post-vaccination titer in ≥ 2 of 4 influenza strains</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have ≥ 4-fold increase in post-vaccination titer in ≥ 3 of 4 influenza strains</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of seroprotection for each strain</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in titer (in GMT) for each strain</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS28-4 (CRP) at 4 weeks after vaccination</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who experience increase in disease activity</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Influenza</condition>
  <condition>Methotrexate</condition>
  <arm_group>
    <arm_group_label>Group 1: MTX continue</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group will continue MTX after vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: MTX hold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will hold MTX for 2 weeks after vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Group 1: MTX continue</arm_group_label>
    <arm_group_label>Group 2: MTX hold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females ≥ 19 years and &lt; 65 years of age at time of consent&#xD;
&#xD;
          -  Have a diagnosis of RA per ACR criteria&#xD;
&#xD;
          -  Must understand and voluntarily sign an informed consent form including writing&#xD;
             consent for data protection&#xD;
&#xD;
          -  Stable doses of methotrexate over the preceding 6 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Previous anaphylactic response to vaccine components or to egg.&#xD;
&#xD;
          -  Acute infection with T &gt;38°C at the time of vaccination&#xD;
&#xD;
          -  History of Guillain-Barre syndrome or demyelinating syndromes&#xD;
&#xD;
          -  Previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2&#xD;
             weeks before the study&#xD;
&#xD;
          -  Blood transfusion within 6 months&#xD;
&#xD;
          -  Active rheumatoid arthritis necessitating a recent change in the drug regimen&#xD;
&#xD;
          -  Any other rheumatic disease such as systemic lupus erythematosus, mixed connective&#xD;
             tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary&#xD;
             Sjogren's disease&#xD;
&#xD;
          -  Any condition including laboratory abnormality which places the subject at&#xD;
             unacceptable risk&#xD;
&#xD;
          -  Subjects who decline to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi-do</state>
        <zip>463-870</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Jong Lee, MD PhD</last_name>
      <phone>+82-31-787-4051</phone>
      <email>leeyn35@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yun Jong Lee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Bong Lee, MD PhD</last_name>
      <phone>82-2-2072-3944</phone>
      <email>leb7616@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Mi Kwon, MD</last_name>
      <phone>82-2-2072-3198</phone>
      <email>hmikwon@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eun Bong Lee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kichul Shin, MD PhD</last_name>
      <phone>+82-2-870-3204</phone>
      <email>kideb1@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kichul Shin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eun Bong Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

